Since the discovery of mTOR as the target of rapamycin in the 1990s, as well as the characterization of mTOR complexes in multiple biological processes in the following decades, the use of rapamycin and its analogues (rapalogs) has been widely studied in various disease contexts including cancer, neurodegeneration, metabolic syndromes, and age-related disorders. The gene discussed is MTOR; the disease is metabolic syndrome.